Versha Banerji

3.0k total citations
68 papers, 754 citations indexed

About

Versha Banerji is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Versha Banerji has authored 68 papers receiving a total of 754 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Genetics, 33 papers in Pathology and Forensic Medicine and 18 papers in Molecular Biology. Recurrent topics in Versha Banerji's work include Chronic Lymphocytic Leukemia Research (49 papers), Lymphoma Diagnosis and Treatment (31 papers) and Immunodeficiency and Autoimmune Disorders (14 papers). Versha Banerji is often cited by papers focused on Chronic Lymphocytic Leukemia Research (49 papers), Lymphoma Diagnosis and Treatment (31 papers) and Immunodeficiency and Autoimmune Disorders (14 papers). Versha Banerji collaborates with scholars based in Canada, United States and United Kingdom. Versha Banerji's co-authors include Spencer B. Gibson, James B. Johnston, Subir Roy Chowdhury, Aaron J. Marshall, Matthew D. Seftel, Marshall Pitz, Iris Gehrke, Armando G. Poeppl, Daniel J. DeAngelo and Kimberly Stegmaier and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Versha Banerji

62 papers receiving 740 citations

Peers

Countries citing papers authored by Versha Banerji

Since Specialization

Citations

This map shows the geographic impact of Versha Banerji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Versha Banerji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Versha Banerji more than expected).

Fields of papers citing papers by Versha Banerji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Versha Banerji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Versha Banerji. The network helps show where Versha Banerji may publish in the future.

Co-authorship network of co-authors of Versha Banerji

This figure shows the co-authorship network connecting the top 25 collaborators of Versha Banerji. A scholar is included among the top collaborators of Versha Banerji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Versha Banerji. Versha Banerji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Scoping Review Mapping Trans* and Gender Diverse People's Representation in Cancer Research 2025 ·Cancer Medicine ·(unknown), (unknown), (unknown), John Queenan, (unknown), Janice Ristock, (unknown), Amanda Ross‐White, Nathan Nickel, Annette Schultz, Versha Banerji, Jacqueline Gahagan, Alyson Mahar	1
2	The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab 2024 ·Cancers ·(unknown), (unknown), Jean Lachaîne, (unknown), (unknown), (unknown), Stéphane Barakat, Beenish S. Manzoor, Christopher Hillis, Versha Banerji	0
3	PI3K-dependent reprogramming of hexokinase isoforms controls glucose metabolism and functional responses of B lymphocytes 2024 ·iScience ·(unknown), (unknown), Edgard M. Mejia, (unknown), (unknown), Grant M. Hatch, Ayesha Saleem, Versha Banerji, Nissim Hay, Hu Zeng, Aaron J. Marshall	2
4	Elevated expression of interleukin 16 in chronic lymphocytic leukemia is associated with disease burden and abnormal immune microenvironment 2023 ·Leukemia Research ·Xun Wu, (unknown), Sen Hou, (unknown), Spencer B. Gibson, James B. Johnston, David E. Dawe, Versha Banerji, Aaron J. Marshall	4
5	A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome 2023 ·Cells ·(unknown), Michèle Rouleau, Laurent Villeneuve, Trang Le, (unknown), Éric P. Allain, (unknown), Sophie Tremblay, (unknown), (unknown), Isabelle Laverdière, Éric Lévesque, Versha Banerji, Katrina Vanura, Chantal Guillemette	1
6	The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry 2023 ·Leukemia & lymphoma ·Rena Buckstein, (unknown), Karen Yee, Michelle Geddes, Heather A. Leitch, (unknown), Versha Banerji, Brian Leber, (unknown), Ève St‐Hilaire, (unknown), Thomas J. Nevill, Mary‐Margaret Keating, John M. Storring, (unknown), (unknown), Derek Tang, (unknown), Chris Cameron, (unknown)	3
7	Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade 2023 ·Current Oncology ·Jiayu Yang, Lin Yang, (unknown), Oliver Bucher, Zoann Nugent, (unknown), (unknown), (unknown), Kevin Brown, (unknown), Aaron J. Marshall, Sachin Katyal, Salaheddin M. Mahmud, Kathleen Decker, (unknown), David E. Dawe, Spencer B. Gibson, James B. Johnston, Versha Banerji	0
8	Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma 2023 ·Nature Communications ·Emma Martell, (unknown), (unknown), (unknown), Subir Roy Chowdhury, (unknown), Agnes Fresnoza, (unknown), Chitra Venugopal, Christopher M. Anderson, Sheila K. Singh, Versha Banerji, Tamra E. Werbowetski‐Ogilvie, Tanveer Sharif	10
9	Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada 2023 ·Current Oncology ·Jean Lachaîne, (unknown), Andrew Aw, Versha Banerji, Isabelle Fleury, Carolyn Owen	9
10	Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia 2022 ·Leukemia Research ·Mirela Anghelina, Michelle J. Naughton, Qiuhong Zhao, Amy S. Ruppert, (unknown), Kerry A. Rogers, James S. Blachly, Gerard Lozanski, Seema A. Bhat, Eric H. Kraut, Narendranath Epperla, Puneet Mathur, Clive S. Zent, Versha Banerji, Claire Dearden, (unknown), Michael R. Grever, Leslie A. Andritsos	1
11	Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells 2021 ·Cancers ·Subir Roy Chowdhury, (unknown), (unknown), Amandeep Singh, James B. Johnston, Spencer B. Gibson, Aaron J. Marshall, Versha Banerji	2
12	Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective 2021 ·Current Oncology ·(unknown), (unknown), Versha Banerji	1
13	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia 2020 ·Leukemia & lymphoma ·Sarit Assouline, Lilian Amrein, Raquel Aloyz, Versha Banerji, Stephen Caplan, Carolyn Owen, Wanda Hasegawa, Sue Robinson, Sudeep Shivakumar, Anca Prica, Anthea Peters, Linda Hagerman, Laura Rodríguez, (unknown), Lawrence Panasci, Bingshu E. Chen, Annette E. Hay	6
14	Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment 2020 ·Cancers ·Subir Roy Chowdhury, (unknown), (unknown), Zoann Nugent, (unknown), Edgard M. Mejia, (unknown), (unknown), (unknown), Donna Hewitt, Linda Davidson, Garry X. Shen, James B. Johnston, Christine A. Doucette, Grant M. Hatch, Paul Fernyhough, Aaron J. Marshall, Spencer B. Gibson, David E. Dawe, Versha Banerji	17
15	Statin Use and Chronic Lymphocytic Leukemia Incidence: A Nested Case–Control Study in Manitoba, Canada 2019 ·Cancer Epidemiology Biomarkers & Prevention ·Christiaan H. Righolt, Geng Zhang, Xibiao Ye, Versha Banerji, James B. Johnston, Spencer B. Gibson, Salaheddin M. Mahmud	9
16	Expression and function of phosphoinositide 3‐kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow 2019 ·British Journal of Haematology ·(unknown), Qingdong Guan, Xun Wu, (unknown), Versha Banerji, James B. Johnston, Donna A. Wall, David Szwajcer, Spencer B. Gibson, Aaron J. Marshall	5
17	IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia 2019 ·Blood Advances ·Ganchimeg Ishdorj, (unknown), Pascal Lambert, (unknown), Salaheddin M. Mahmud, Spencer B. Gibson, Versha Banerji, Aaron J. Marshall, James B. Johnston	20
18	On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells 2014 ·Clinical Cancer Research ·Iris Gehrke, (unknown), (unknown), Armando G. Poeppl, James B. Johnston, Spencer B. Gibson, Versha Banerji	61
19	Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling 2014 ·Cell Death and Disease ·Rebecca Dielschneider, Wenwu Xiao, (unknown), Eui‐Kyu Noh, Versha Banerji, (unknown), Aaron J. Marshall, James B. Johnston, Spencer B. Gibson	12
20	The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia 2012 ·Journal of Clinical Investigation ·Versha Banerji, Stacey M. Frumm, Kenneth N. Ross, Loretta S. Li, Anna C. Schinzel, Cynthia K. Hahn, Rose M. Kakoza, Kwan T. Chow, Linda S. Ross, Gabriela Alexe, Nicola Tolliday, Haig Inguilizian, Ilene Galinsky, Richard M. Stone, Daniel J. DeAngelo, Giovanni Roti, Jon C. Aster, William C. Hahn, Andrew L. Kung, Kimberly Stegmaier	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact